

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: HKG4/21 - Haemocoagulation Tests

Deadline: 19.11.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability								
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(170) APTT - ratio					306							295	288	98%	
--- Samples and groups ---	[-]														
Sample A		1,10	0,084	7,7	306							295	294	100%	
(0) Not specified; (240) Siemens (Dade) Actin FS		1,14	0,05	4,4	94	0	CVPG	1,14	0,013	20%	0,912	1,37	94		
(0) Not specified; (241) Siemens (Dade) Actin FSL		1,01	0,036	3,5	27	0	CVPG	1,01	0,017	20%	0,808	1,22	27		
(0) Not specified; (242) Siemens (Dade) Pathromtin SL		1,15	0,045	4,0	81	0	CVPG	1,15	0,012	20%	0,92	1,38	81		
(0) Not specified; (246) Mindray APTT Reagent		0,995	0,037	3,7	9	0	CVPG	0,995	0,046	20%	0,796	1,2	9		
(0) Not specified; (253) IL APTT-SP		0,952	0,051	5,3	23	0	CVPG	0,952	0,026	20%	0,761	1,15	23		
(0) Not specified; (256) IL SynthASil		1,13	0,049	4,3	11	0	CVPG	1,13	0,036	20%	0,904	1,36	11		
(0) Not specified; (257) Diagon Dia-PTT-Liquid		1,09	0,037	3,4	9	0	CVPG	1,09	0,046	20%	0,872	1,31	9		
(0) Not specified; (260) Stago PTT Automate		1,05	0,043	4,1	16	0	CVPG	1,05	0,026	20%	0,84	1,26	16		
(0) Not specified; (265) Stago Cephascreen		1,05	0,049	4,6	16	0	CVPG	1,05	0,030	20%	0,84	1,26	16		
(0) Not specified; (266) Hyphen BioMed CEPHEN		1,12	0,037	3,3	9	0	CVPG	1,12	0,046	20%	0,896	1,35	9		
Other					11	0							0		
								1x 0/248, 2x 0/259, 4x 0/269, 1x 0/270, 3x 0/999							
Sample B		2,45	0,44	18	306							295	289	98%	
(0) Not specified; (240) Siemens (Dade) Actin FS		2,37	0,14	5,7	94	0	CVPG	2,37	0,034	20%	1,89	2,85	94		
(0) Not specified; (241) Siemens (Dade) Actin FSL		1,88	0,12	6,6	27	0	CVPG	1,88	0,058	20%	1,5	2,26	27		
(0) Not specified; (242) Siemens (Dade) Pathromtin SL		3,00	0,16	5,2	81	1	CVPG	3	0,043	20%	2,4	3,6	81		
(0) Not specified; (246) Mindray APTT Reagent		2,32	0,10	4,5	9	0	CVPG	2,32	0,13	20%	1,85	2,79	9		
(0) Not specified; (253) IL APTT-SP		2,09	0,12	5,5	23	0	CVPG	2,09	0,059	20%	1,67	2,51	23		
(0) Not specified; (256) IL SynthASil		2,04	0,12	5,8	11	0	CVPG	2,04	0,087	20%	1,63	2,45	11		
(0) Not specified; (257) Diagon Dia-PTT-Liquid		2,62	0,20	7,7	9	0	CVPG	2,62	0,25	20%	2,09	3,15	9		
(0) Not specified; (260) Stago PTT Automate		2,23	0,088	3,9	16	0	CVPG	2,23	0,054	20%	1,78	2,68	16		
(0) Not specified; (265) Stago Cephascreen		2,11	0,13	6,3	16	0	CVPG	2,11	0,081	20%	1,68	2,54	16		
(0) Not specified; (266) Hyphen BioMed CEPHEN		2,63	0,037	1,4	9	0	CVPG	2,63	0,046	20%	2,1	3,16	9		
Other					11	0							0		
								1x 0/248, 2x 0/259, 4x 0/269, 1x 0/270, 3x 0/999							
(171) Fibrinogen					237							237	229	97%	
--- Samples and groups ---	[g/L]														
Sample A		3,25	0,22	6,8	237		CVP	3,25	0,035	25%	2,43	4,07	237	233	98%
(1) Coagulometer		3,25	0,22	6,8	237	0							237		
Sample B		1,43	0,14	10	237		CVP	1,43	0,023	25%	1,07	1,79	237	231	97%
(1) Coagulometer		1,43	0,14	10	237	0							237		
(177) Antithrombin					171							171	162	95%	
--- Samples and groups ---	[%]														
Sample A		106	5,1	4,9	171		CVP	106	0,96	18%	86,9	126	171	170	99%
(1) Coagulometer		105	7,6	7,2	10	0							10		
(4) Chromogenous substrat		106	5,1	4,8	161	0							161		
Sample B		55,0	4,5	8,2	171		CVP	55	0,85	18%	45,1	64,9	171	162	95%
(1) Coagulometer		57,6	7,0	12	10	0							10		
(4) Chromogenous substrat		54,8	4,4	8,0	161	0							161		
(172) Prothrombin test (INR)					315							306	295	96%	
--- Samples and groups ---	[-]														
Sample A		1,03	0,052	5,1	315		CVP	1,03	0,072	20%	0,824	1,24	315	314	100%
(1) Coagulometr (trom. human plac.)		1,03	0,053	5,1	198	0							198		
(2) Coagulometr (trom. human rec.)		1,03	0,051	5,0	55	0							55		
(3) Coagulometr (trom. rabbit br.)		1,03	0,05	4,8	62	0							62		
Sample B		2,94	0,30	10	315							306	295	96%	
(1) Coagulometr (trom. human plac.)		3,01	0,25	8,2	197	0	CVP	2,96	0,040	20%	2,36	3,56	197		
(2) Coagulometr (trom. human rec.)		2,68	0,20	7,5	47	0	CVP	2,96	0,040	20%	2,36	3,56	47		
(2) Coagulometr (trom. human rec.); (177) Mindray		1,89	0,12	6,3	8	0	CVPG	1,92	0,10	20%	1,53	2,31	0		
(3) Coagulometr (trom. rabbit br.)		2,99	0,28	9,4	62	0	CVP	2,96	0,040	20%	2,36	3,56	62		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: HKG4/21 - Haemocoagulation Tests

Deadline: 19.11.2021

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(172) Prothrombin test (INR)	[-]				315								306	295	96%
Samples and groups															
Sample B		2,94	0,30	10	315								306	295	96%
Other					1	0							0		
1x 1/177															
(179) Prothrombin test (ratio)	[-]				313								304	291	96%
Samples and groups															
Sample A		1,03	0,051	4,9	313	CVP	1,03	0,0070	20%	0,824	1,24		313	312	100%
(1) Coagulometr (trom. human plac.)		1,03	0,052	5,0	199	0							199		
(2) Coagulometr (trom. human rec.)		1,03	0,053	5,1	57	0							57		
(3) Coagulometr (trom. rabbit br.)		1,02	0,049	4,7	57	0							57		
Sample B		2,86	0,27	9,5	313								304	292	96%
(1) Coagulometr (trom. human plac.)		2,95	0,23	8,0	198	0	CVP	2,87	0,036	20%	2,29	3,45	198		
(2) Coagulometr (trom. human rec.)		2,71	0,20	7,3	49	0	CVP	2,87	0,036	20%	2,29	3,45	49		
(2) Coagulometr (trom. human rec.); (177) Mindray		1,94	0,14	7,3	8	0	CVPG	1,95	0,11	20%	1,56	2,34	0		
(3) Coagulometr (trom. rabbit br.)		2,73	0,29	11	57	0	CVP	2,87	0,036	20%	2,29	3,45	57		
Other					1	0							0		
1x 1/177															
(173) Thrombin time (time)	[s]				153								134	128	96%
Samples and groups															
Sample A		16,9	1,9	11	153								134	131	98%
(3) Thrombin units: 1,5 IU/mL (NIH); (94) Stago		18,1	0,81	4,5	16	0	CVPG	18,1	0,50	20%	14,4	21,8	16		
(3) Thrombin units: 1,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		20,4	1,4	6,9	6	0	CVPG	20,4	2,0	20%	16,3	24,5	6		
(5) Thrombin units: 2,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		15,8	1,2	7,7	80	0	CVPG	15,8	0,33	20%	12,6	19	80		
(6) Thrombin units: 3 IU/mL (NIH); (38) IL		17,9	1,0	5,7	20	0	CVPG	17,9	0,56	20%	14,3	21,5	20		
(7) Thrombin units: 5 IU/mL (NIH); (175) DIAGON		20,7	3,9	19	7	0	CVPG	20,7	3,8	20%	16,5	24,9	7		
(8) Thrombin units: 8 IU/mL (NIH); (177) Mindray		17,1	0,89	5,2	5	0	CVPG	17,1	2,5	20%	13,6	20,6	5		
Other					19	0							0		
1x 1/38, 1x 1/126, 4x 1/149, 2x 1/175, 1x 1/179, 1x 2/149, 1x 2/193, 4x 5/179, 1x 6/998, 2x 7/38, 1x 99/46															
Sample B		20,6	5,3	26	153								134	130	97%
(3) Thrombin units: 1,5 IU/mL (NIH); (94) Stago		23,5	0,75	3,2	16	0	CVPG	23,5	0,46	20%	18,8	28,2	16		
(3) Thrombin units: 1,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		22,9	1,6	6,8	6	0	CVPG	22,9	2,2	20%	18,3	27,5	6		
(5) Thrombin units: 2,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		17,1	1,0	6,1	80	0	CVPG	17,1	0,29	20%	13,6	20,6	80		
(6) Thrombin units: 3 IU/mL (NIH); (38) IL		30,1	1,5	5,0	20	0	CVPG	30,1	0,82	20%	24	36,2	20		
(7) Thrombin units: 5 IU/mL (NIH); (175) DIAGON		26,5	2,2	8,4	7	0	CVPG	26,5	2,2	20%	21,2	31,8	7		
(8) Thrombin units: 8 IU/mL (NIH); (177) Mindray		22,8	1,0	4,4	5	0	CVPG	22,8	2,8	20%	18,2	27,4	5		
Other					19	0							0		
1x 1/38, 1x 1/126, 4x 1/149, 2x 1/175, 1x 1/179, 1x 2/149, 1x 2/193, 4x 5/179, 1x 6/998, 2x 7/38, 1x 99/46															
(174) Thrombin time (ratio)	[-]				135								119	115	97%
Samples and groups															
Sample A		1,04	0,10	10	135								119	117	98%
(3) Thrombin units: 1,5 IU/mL (NIH); (94) Stago		1,01	0,056	5,5	15	0	CVPG	1,01	0,035	20%	0,808	1,22	15		
(3) Thrombin units: 1,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		1,09	0,13	12	5	0	CVPG	1,09	0,36	20%	0,872	1,31	5		
(5) Thrombin units: 2,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		0,993	0,072	7,3	69	0	CVPG	0,993	0,021	20%	0,794	1,2	69		
(6) Thrombin units: 3 IU/mL (NIH); (38) IL		1,21	0,10	8,7	18	0	CVPG	1,21	0,060	20%	0,968	1,46	18		
(7) Thrombin units: 5 IU/mL (NIH); (175) DIAGON		1,07	0,089	8,3	7	0	CVPG	1,07	0,086	20%	0,856	1,29	7		
(8) Thrombin units: 8 IU/mL (NIH); (177) Mindray		1,07	0,11	10	5	0	CVPG	1,07	0,31	20%	0,856	1,29	5		
Other					16	0							0		
1x 1/38, 1x 1/126, 2x 1/149, 2x 1/175, 1x 2/94, 1x 2/149, 1x 2/193, 2x 5/179, 1x 6/51, 1x 6/998, 2x 7/38, 1x 99/46															
Sample B		1,24	0,26	21	135								119	115	97%
(3) Thrombin units: 1,5 IU/mL (NIH); (94) Stago		1,32	0,071	5,3	15	0	CVPG	1,32	0,045	20%	1,05	1,59	15		
(3) Thrombin units: 1,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		1,32	0,17	13	5	0	CVPG	1,32	0,48	20%	1,05	1,59	5		
(5) Thrombin units: 2,5 IU/mL (NIH); (149) Siemens (Dade, BN, Dimension)		1,07	0,073	6,8	69	0	CVPG	1,07	0,021	20%	0,856	1,29	69		
(6) Thrombin units: 3 IU/mL (NIH); (38) IL		2,03	0,18	8,9	18	0	CVPG	2,03	0,10	20%	1,62	2,44	18		
(7) Thrombin units: 5 IU/mL (NIH); (175) DIAGON		1,35	0,074	5,5	7	0	CVPG	1,35	0,072	20%	1,08	1,62	7		
(8) Thrombin units: 8 IU/mL (NIH); (177) Mindray		1,41	0,15	11	5	0	CVPG	1,41	0,42	20%	1,12	1,7	5		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: HKG4/21 - Haemocoagulation Tests

Deadline: 19.11.2021

Test	[unit]	ROM	SD	CV [%]	N _{tot}	N _{out}	Comparability								
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(174) Thrombin time (ratio)					135							119	115	97%	
Samples and groups	[-]														
Sample B		1,24	0,26	21	135							119	115	97%	
Other					16	0								0	
							1x 1/38, 1x 1/126, 2x 1/149, 2x 1/175, 1x 2/94, 1x 2/149, 1x 2/193, 2x 5/179, 1x 6/51, 1x 6/998, 2x 7/38, 1x 99/46								

st_kn_p

End of report

Printed: 01.12.2021